March 18, 2008 – Teva Health Systems is pleased to announce the introduction and availability of Ciprofl oxacin Injection, USP (In 5% Dextrose). This product is AP rated to Cipro®* I.V. for Intravenous Infusion. Ciprofl oxacin Injection is available in 2 mg/mL, 200 mg and 2 mg/mL, 400 mg in fl exible plastic containers.
“Teva offers a broad range of quality health systems generics from a single source,” states Jonathan Zalk, Director of Marketing. “We are pleased to announce this latest addition to our growing line.”
Teva Health Systems is a part of Teva Pharmaceuticals, the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.
No comments:
Post a Comment